| Screen, Inc.
is seeking qualified investors in a single stock subscription. The minimum
stock contract is for $25,000. |
||
|
The flattening of the world brought
3 billion new consumers onto the playing field, all with aging populations.
As soon as a drug appears that will stop, or even substantially slow,
the progression into Alzheimer's disease, the demand for a tool that detects
the first signs of decline will explode. People the world over will want
the decline stopped as early in the disease process as possible. The CANS-MCI
is the most economical, effective tool for that detection. In most countries,
it can fill a tremendous void with respect to available neuropsychological
assessment. It is already available in Portuguese for Brazil, Spanish
for South America and the US, Nederlands (Dutch) for Europe, and English
specific to the US, Canada and the UK. Nearly one half of all AD patients are not diagnosed until they have reached a significant degree of decline known as "Moderate AD", long past the time for maximum delay of disease progression. Currently, very few are detected earlier than when they exhibit "Mild AD". Earlier identification of the impairments that progress to AD can improve family awareness and slow functional decline, delaying placement in nursing homes. Each single year of delayed progression in each afflicted person might save an average of $47,000 in direct nursing expenses and thousands in related medical expenses and avoided injuries. The savings from early screening would make a positive impact on the current $61 billion a year in costs related to Alzheimer's disease incurred by U.S. business, and the $100 billion incurred by U.S. citizens. Every correct indication that a full neuropsychological evaluation is recommended could already save between six months and two years of patient time out of an assisted care facility by resulting in family action and medical treatment that delays functional deterioration. The quality of life improvements due to earlier detection are not quantifiable. Screen, Inc. was founded in 1997 to develop next-generation devices for automated cognitive ability screening. The company's mission is to provide innovative, practical, and cost-effective products that facilitate rapid screening for pre-dementia and other conditions within the setting of a physician's office. Automated testing, touch screen technology, multimedia interactive programming, and treatments for dementia have all emerged dramatically and simultaneously to enhance the profitability of this undertaking. The extensive, NIH-supported research results fully support the use of the CANS-MCI for early screening. The CANS-MCI stands out in many ways: It accurately measures the very earliest signs of deterioration. It is objective, administered without interpersonal embarrassment, multidimensional, useful for longitudinal tracking, and can be embedded in annual physicals without additional staff time. It is the only tool that combines thorough objective assessment with high cost effectiveness. The primary current competition, the Mini Mental Status Exam (MMSE), is useful for the measurement of established dementia and not known to be predictive enough of AD to warrant use for mass screening. There are currently available commercial screening instruments, but most are one-dimensional and useless for tracking changes, such as a clock test, a paragraph recall test, a three-item recall test, or naming fluency for objects in one category. One-dimensional tests do not offer an adequate range of scores for longitudinal tracking (if scores that can be compared to one another are involved at all), nor do they take into account the wide variety of initial presentations of AD. The lack of truly efficient, objective tests that avoid embarrassment and resistance at annual physicals may be partially responsible for the failure to detect most cases of Alzheimer's disease before it is too late to effectively stall the disease. The CANS-MCI is uniquely cost effective for doctors in terms of staff time for test administration, scoring, interpretation, and staff training. It is the only set of tests that can be administered without the presence, much less the training, of a staff member. Efficient, automated administration and scoring of tests that measure changes in the full range of cognitive abilities are the primary advantages we have over all competition. The CANS-MCI also has the ability to send and receive information from our central server and database. This allows for immediate, automated, scoring, along with the benefits of centralized data storage (longitudinal graphical display, retroactive refinements in the formulas evaluating scores, return of reports in a language other than that used for test administration). Automation allows for the immediate expansion of testing, as soon as a facility, here or abroad, acquires a touch screen (cost in US = $400). The US version offers administration in either English or Spanish. Version are now available for Brazil (Portuguese), South America (Spanish), Nederlands (all of Europe), and specific to the UK and Canada in English. Versions are under development in French (specific to France and specific to Canada), Finnish (for Europe), and Caribe Spanish (Cuban dialect). Up until 1997, the early detection of impairments only allowed for more time to plan nursing care, and more time to put the AD patient's affairs in order. In 1997, 2.3 million Americans had Alzheimer's disease (AD), with about 460,000 new cases diagnosed each year. At age 62, an American has a 1 in 1000 chance of developing AD; from age 60 the prevalence doubles every 5 years. In 1998, drug treatments that delay Alzheimer's progression began in earnest with TacrineTM, and then AriceptTM, ReminylTM, NamendaTM, and ExcelonTM. Risk reduction also began to receive more serious attention, with the recognition of physical exercise, mental activity, statins, anti-oxidants and anti-inflammatory drugs as important correlates of reduced risk. If these and other new drugs can be used to delay the onset of AD, the number of Americans who acquire AD will decline significantly, even without a major treatment breakthrough. [1] Early identification of the mild cognitive impairments that progress to AD would reduce the rate of disease progression and delay placement in a nursing home. [2] The discovery of symptom-delaying medications has caused the market for early detection to explode. There are 50 million people in the US over 60 and a billion people in the world over 60, the age at which routine screening for cognitive impairment could be usefully started. [3] Medications that reverse the disease process will markedly increase the demand for early detection. Screen, Inc. is in the business of creating, validating, and distributing automated medical screening tests that provide doctors with critical cost effective information. The present cost of this information is so high that it often goes uncollected. Our automated, self-administered test battery, called the Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment (CANS-MCI), has been created, refined, scientifically validated through rigorous NIH-supported research, and is now being distributed as a research tool. Our mission is to provide innovative, practical, top-quality products that save time and improve the medical screening for dementia and other conditions. We believe our first responsibility is to the older adults at risk of developing dementia. Our strong scientific basis and technical efficiency enables us to provide low-cost, time-saving screening procedures to older adults via their doctors. The tests can be administered at a doctor's office, senior center, or retirement home. We offer a way to economically track changes in cognitive ability so that the earliest possible treatments for Mild Cognitive Impairment and dementia of the Alzheimer's type can be detected and treated. The CANS-MCI tests were developed from 1998 through 2000 and tested for
usability, reliability and validity from 1999 through 2004. Since
then, we have introduced the CANS-MCI on a CD-ROM for easy installation
and for eventual use in multiple languages, according to the doctor's
preferences. The web-based interactive components, automated scoring
and report-writing algorithms allow us to return immediate graphical and
text displays of the results to the doctor. In our field the "Customer"
means the doctor/patient team. We must appeal to doctors in terms
of cost, scientific validity, and clinical utility. However, a large
part of the clinical utility is also related to our advantages with respect
to how we appeal to the patients. Usability is the key, since the
goal is to help patients repeatedly by offering them a valuable, pleasant
product, by far the most pleasant screening procedure on the market. Features/Benefits Over CompetitionOur products have the features of automated, consistent test administration at low cost that provide more objective assessment without interpersonal embarrassment. All products from Screen, Inc. have objective, quantifiable (scaled) scores with which changes in emotional state, alcohol use, and cognitive ability can be assessed over time. Questions concerning these factors allow the CANS-MCI to generate recommendations with a high degree of specificity concerning the probable cause of poor scores and the best use of re-testing and professional referrals to clarify the exact impairments involved. The capability for longitudinal comparisons means that people who otherwise might be able to mask cognitive decline because of their superior cognitive reserve ability, as well as people who tend to deny existing changes, can be followed accurately without undue stress, embarrassment, or interference with the doctor-patient relationship. This is a unique feature enjoyed by CANS-MCI customers. The major benefits of the CANS-MCI are:
These combined capabilities, in by far the most pleasant screening procedure
on the market, provide the earliest, most objective, least intrusive,
and least costly measurement of changes in emotional state and cognitive
abilities that are predictive of Alzheimer's disease. Once diagnosed,
the tests can be used to evaluate patients' responses to medications designed
to reverse or stall the progression of dementia and/or depression.
Our product will provide the evaluation of several cognitive domains,
resulting in refined scoring algorithms that can suggest the further evaluation
for possible disorders, e.g. vascular components of dementia, the contribution
of depression or current alcohol use to dementia. Notes 1. American Journal of Public Health 88:1337 March 16,
1999.
Please select, copy,
print, sign and send the following,
INVESTOR QUALIFICATION ACKNOWLEDGEMENT If you wish to receive an executive summary of the business plan, please review, sign and send the following acknowledgement. The undersigned hereby certifies that the undersigned is an “accredited investor” (as that term is defined in Rule 501(a) under the Securities Act) because the undersigned falls within at least one of the following categories: • an individual whose individual net worth, or joint net worth with that individual’s spouse, exceeds $1,000,000 (including the value of homes, home furnishings and personal automobiles); • an individual who had an individual income in excess of $200,000 in each of the last two calendar years or joint income with that person’s spouse in excess of $300,000 in each of those years and who reasonably expects to reach the same income level in the current year. For purposes of this Offering, individual income shall equal adjusted gross income, as reported in the investor’s federal income tax return, less any income attributable to a spouse or to property owned by the spouse; or
Screen, Inc.
Print Name _________________________ Street Street/Apt # City, State, Zip Code
Email Address:
|
